WHO confronts Chinese company over malaria drugBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39154.358762.DB (Published 15 March 2007) Cite this as: BMJ 2007;334:553
- Anne Glusker
The World Health Organization is asking a Chinese pharmaceutical company to stop making a malaria drug that earns millions of dollars annually in revenues.
The move is part of a campaign to combat increasing resistance to antimalarials and to promote use of combination treatments. The drug's manufacturer, Kunming Pharmaceutical, which is owned by the Holley Group and publicly traded on the Shanghai Stock Exchange, is refusing to halt sales, which amounted to $5m (£2.6m; €3.8m) in 2004, according to the Wall Street Journal (http://online.wsj.com, 6 Mar, “China's pride on line in malaria clash”).
The confrontation may prove awkward for Margaret Chan, the newly elected director general of WHO, who is from Hong Kong. One of the questions raised about Chan's …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial